Breaking News Instant updates and real-time market news.

CRSP

Crispr Therapeutics

$16.75

-0.15 (-0.89%)

, NTLA

Intellia Therapeutics

$15.23

-0.88 (-5.46%)

09:51
08/03/17
08/03
09:51
08/03/17
09:51

Crispr stocks rise after scientists successfully fix disease mutation in embryo

Shares of Crispr Therapeutics are rising in early trading after a team of scientists reported that they were successful in editing the DNA in human embryos to correct a pathogenic gene mutation. The study, published online Wednesday in the journal Nature, described the correction of the heterozygous MYBPC3 mutation in human preimplantation embryos with "precise CRISPR-Cas9-based targeting accuracy and high homology-directed repair efficiency by activating an endogenous, germline-specific DNA repair response." Crispr Therapeutics (CRSP), which is a publicly traded company pursuing CRISPR treatments, is up 2.6% in early trading. Intellia Therapeutics (NTLA) and Editas Medicine (EDIT), which are also pursuing CRISPR treatments, are up 1.5% and 7.5%, respectively. Reference Link

CRSP

Crispr Therapeutics

$16.75

-0.15 (-0.89%)

NTLA

Intellia Therapeutics

$15.23

-0.88 (-5.46%)

EDIT

Editas Medicine

$15.81

-0.58 (-3.54%)

  • 15

    Aug

CRSP Crispr Therapeutics
$16.75

-0.15 (-0.89%)

02/16/17
PIPR
02/16/17
NO CHANGE
Target $21
PIPR
Overweight
Piper's Schimmer calls CRISPR selloff 'major overreaction'
Piper Jaffray analyst Joshua Schimmer views yesterday's selloff in shares of CRISPR Therapeutics (CRSP) as a "major overreaction." The stock closed yesterday down 8%, or $1.36, to $15.90 after the patent office did not allow the patent interference with UC Berkeley versus Broad Institute over a Crispr/Cas-9 patent. Now that it's deemed patentable, CRISPR will move forward to get its own claims issued and likely move towards a second interference, Schimmer tells investors in a research note. CRISPER and Intellia Therapeutics (NTLA) are essentially litigation partners against the Broad, and now have the chance to win by knocking out Editas Medicine's (EDIT) single-guide tracr patent or by showing it was the first to invent and reduce to practice the application in eukaryotes, the analyst contends. Schimmer says he can't understand why Editas' valuation is higher than CRISPR's. He believes it should be the opposite. The analyst keeps an Overweight rating on CRISPR with a $21 price target.
03/28/17
CHDN
03/28/17
INITIATION
Target $23.5
CHDN
Buy
CRISPR Therapeutics initiated with a Buy at Chardan
Chardan analyst Madhu Kumar initiated CRISPR Therapeutics with a Buy and a $23.50 price target saying upside from clinical leadership in CRISPR therapy offsets any potential downside from its IP exposure.
07/13/17
RHCO
07/13/17
INITIATION
Target $16
RHCO
Hold
CRISPR Therapeutics initiated with a Hold at SunTrust
SunTrust analyst Peter Larson initiated CRISPR Therapeutics with a Hold and a $16 price target.
07/17/17
OPCO
07/17/17
INITIATION
OPCO
Perform
Crispr Therapeutics initiated with a Perform at Oppenheimer
Oppenheimer analyst Leah Rush Cann started Crispr Therapeutics (CRSP) with a Perform rating saying the company is in a weaker patent position than competitor Editas Medicine (EDIT).
NTLA Intellia Therapeutics
$15.23

-0.88 (-5.46%)

07/17/17
OPCO
07/17/17
INITIATION
OPCO
Perform
Intellia Therapeutics initiated with a Perform at Oppenheimer
Oppenheimer analyst Leah Rush Cann stated Intellia Therapeutics (NTLA) with a Perform rating saying the company is currently in a weaker patent position than competitor Editas Medicine (EDIT). The analyst, however, believes Intellia has the strongest partners among the CRISPR-based companies.
05/03/17
FBCO
05/03/17
NO CHANGE
Target $24
FBCO
Outperform
Intellia Therapeutics price target lowered to $24 from $39 at Credit Suisse
Credit Suisse analyst Alethia Young lowered her price target for Intellia Therapeutics to $24 from $39 saying that while she still likes it, big upside is likely capped until the company moves forward toward proof of concept. Young reiterates an Outperform rating on the shares.
05/31/17
JEFF
05/31/17
NO CHANGE
Target $33
JEFF
Buy
Intellia Therapeutics weakness a buying opportunity, says Jefferies
Jefferies analyst Maury Raycroft said weakness in Intellia Therapeutics shares in reaction to an article published in Nature Methods is a buying opportunity. The analyst said the story is "flawed overall" as it draws conclusions based on assessment of two experiments in mice that have different genetic makeup compared to a single control mouse, combined with other genetic variables, that may explain the article's conclusions. Raycroft said the story should not impact shares and reiterates his Buy rating and $33 price target on Intellia Therapeutics.
07/20/17
JEFF
07/20/17
NO CHANGE
Target $36
JEFF
Buy
Intellia should be bought for long-term opportunity, says Jefferies
After touring the company's labs, Jefferies analyst Maury Raycroft recommends buying shares of Intellia Therapeutics for the company's long-term opportunity. The analyst keeps a Buy rating on the shares with a $36 price target.
EDIT Editas Medicine
$15.81

-0.58 (-3.54%)

07/17/17
OPCO
07/17/17
INITIATION
OPCO
Perform
Editas Medicine initiated with a Perform at Oppenheimer
Oppenheimer analyst Leah Rush Cann started Editas Medicine (EDIT) with a Perform rating saying that while the company currently has the strongest patent position among its CRISPR-based peers, the shares are fairly valued.
07/13/17
RHCO
07/13/17
INITIATION
Target $17
RHCO
Hold
Editas Medicine initiated with a Hold at SunTrust
SunTrust analyst Peter Larson initiated Editas Medicine with a Hold and a $17 price target.

TODAY'S FREE FLY STORIES

KKR

KKR

$18.56

-0.085 (-0.46%)

13:31
08/23/17
08/23
13:31
08/23/17
13:31
Periodicals
KKR considers sale of French gas-fired power plants, Reuters reports »

KKR is mulling the sale…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSEM

Tower Semiconductor

$27.12

0.7 (2.65%)

13:30
08/23/17
08/23
13:30
08/23/17
13:30
Options
Bullish flow in Tower Semi as shares set 52-week highs »

Bullish flow in Tower…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 06

    Sep

13:30
08/23/17
08/23
13:30
08/23/17
13:30
General news
NY Fed accepted $169.8 B in daily reverse repos »

NY Fed accepted $169.8 B…

OMER

Omeros

$21.29

0.49 (2.36%)

13:22
08/23/17
08/23
13:22
08/23/17
13:22
Periodicals
Omeros 'still won't answer basic questions,' STAT's Feuerstein says »

Omeros' press…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PUB

People's Utah Bancorp

$27.00

0.05 (0.19%)

13:20
08/23/17
08/23
13:20
08/23/17
13:20
Hot Stocks
People's Utah Bancorp CEO sells 12,170 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTL

CenturyLink

$20.44

0.54 (2.71%)

13:20
08/23/17
08/23
13:20
08/23/17
13:20
Options
Second day of interest in CenturyLink September puts »

Second day of interest in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PETS

PetMed Express

$39.41

-2.32 (-5.56%)

13:17
08/23/17
08/23
13:17
08/23/17
13:17
Hot Stocks
PetMed Express tells Bloomberg Aurelius report 'false and defamatory' »

In response to an earlier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Sep

$NSD

NASDAQ Market Internals

13:17
08/23/17
08/23
13:17
08/23/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRE

Sempra Energy

$118.03

-0.25 (-0.21%)

13:16
08/23/17
08/23
13:16
08/23/17
13:16
Conference/Events
Sempra Energy to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Aug

  • 14

    Sep

$NYE

NYSE Market Internals

13:16
08/23/17
08/23
13:16
08/23/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
08/23/17
08/23
13:15
08/23/17
13:15
General news
Jackson Hole outlook: »

Jackson Hole outlook: the…

CAVM

Cavium

$60.98

0.84 (1.40%)

13:15
08/23/17
08/23
13:15
08/23/17
13:15
Conference/Events
Cavium has a conference call hosted by William Blair »

William Blair Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 23

    Aug

  • 06

    Sep

PETS

PetMed Express

$39.41

-2.32 (-5.56%)

13:12
08/23/17
08/23
13:12
08/23/17
13:12
Recommendations
PetMed Express analyst commentary  »

PetMed Express recent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Sep

SIX

Six Flags

$51.97

-1.25 (-2.35%)

, DIS

Disney

$102.04

-0.73 (-0.71%)

13:06
08/23/17
08/23
13:06
08/23/17
13:06
Hot Stocks
Six Flags Magic Mountain to launch 365-day operation on January 1 »

Six Flags Entertainment…

SIX

Six Flags

$51.97

-1.25 (-2.35%)

DIS

Disney

$102.04

-0.73 (-0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

S

Sprint

$8.29

0.065 (0.79%)

, SSNLF

Samsung

$2,030.00

-70 (-3.33%)

13:05
08/23/17
08/23
13:05
08/23/17
13:05
Hot Stocks
Samsung Galaxy Note8 coming to Sprint for $20 a month »

Sprint (S) announced the…

S

Sprint

$8.29

0.065 (0.79%)

SSNLF

Samsung

$2,030.00

-70 (-3.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

WSM

Williams-Sonoma

$43.04

0.19 (0.44%)

13:05
08/23/17
08/23
13:05
08/23/17
13:05
Options
Williams Sonoma call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

MSI

Motorola Solutions

$86.67

0.26 (0.30%)

, ZURVY

Zurich Insurance

$30.34

-0.04 (-0.13%)

13:04
08/23/17
08/23
13:04
08/23/17
13:04
Hot Stocks
Motorola Solutions names Troy Mattern as head of product cybersecurity »

Motorola Solutions (MSI)…

MSI

Motorola Solutions

$86.67

0.26 (0.30%)

ZURVY

Zurich Insurance

$30.34

-0.04 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

HPQ

HP Inc.

$18.91

-0.115 (-0.60%)

, HPE

HP Enterprise

$17.69

0.02 (0.11%)

12:56
08/23/17
08/23
12:56
08/23/17
12:56
Earnings
On The Fly: What to watch in HP Inc.'s earnings report »

HP Inc. (HPQ) is…

HPQ

HP Inc.

$18.91

-0.115 (-0.60%)

HPE

HP Enterprise

$17.69

0.02 (0.11%)

LNVGY

Lenovo

$11.13

-0.07 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 29

    Aug

  • 29

    Aug

  • 31

    Aug

  • 01

    Sep

  • 05

    Sep

  • 06

    Sep

BABA

Alibaba

$173.90

-0.562 (-0.32%)

12:55
08/23/17
08/23
12:55
08/23/17
12:55
Periodicals
Breaking Periodicals news story on Alibaba »

Alibaba mentioned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ON

ON Semiconductor

$16.04

0.29 (1.84%)

12:55
08/23/17
08/23
12:55
08/23/17
12:55
Periodicals
Breaking Periodicals news story on ON Semiconductor »

ON Semiconductor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Sep

KRO

Kronos Worldwide

$19.25

-0.25 (-1.28%)

12:55
08/23/17
08/23
12:55
08/23/17
12:55
Periodicals
Breaking Periodicals news story on Kronos Worldwide »

Kronos Worldwide…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:55
08/23/17
08/23
12:55
08/23/17
12:55
General news
U.S. VIX equity volatility is up 4% near 11.82 »

U.S. VIX equity…

HCCI

Heritage-Crystal Clean

$18.15

-0.05 (-0.27%)

12:54
08/23/17
08/23
12:54
08/23/17
12:54
Periodicals
Breaking Periodicals news story on Heritage-Crystal Clean »

Heritage-Crystal Clean…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Aug

  • 08

    Sep

  • 09

    Sep

12:50
08/23/17
08/23
12:50
08/23/17
12:50
General news
Breaking General news story  »

Dallas Federal Reserve…

CVM

CEL-SCI

$1.95

-0.341 (-14.89%)

12:47
08/23/17
08/23
12:47
08/23/17
12:47
Hot Stocks
Breaking Hot Stocks news story on CEL-SCI »

Sabby Management reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.